William Blair Issues Positive Forecast for IPSC Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Analysts at William Blair lifted their Q1 2025 earnings per share estimates for Century Therapeutics in a research note issued on Thursday, March 20th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.45) for the quarter, up from their prior estimate of ($0.46). The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. William Blair also issued estimates for Century Therapeutics’ Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.79) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($1.89) EPS.

Several other research analysts have also commented on the stock. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Piper Sandler lowered their target price on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, Guggenheim reduced their price target on Century Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a research report on Friday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Century Therapeutics has a consensus rating of “Buy” and a consensus price target of $5.80.

Century Therapeutics Stock Performance

Shares of IPSC opened at $0.56 on Monday. The firm has a market cap of $47.19 million, a PE ratio of -0.30 and a beta of 1.75. The firm’s 50 day moving average price is $0.74 and its 200 day moving average price is $1.15. Century Therapeutics has a twelve month low of $0.52 and a twelve month high of $4.50.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.02. The company had revenue of $4.18 million during the quarter, compared to the consensus estimate of $0.67 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IPSC. Marshall Wace LLP acquired a new stake in shares of Century Therapeutics in the fourth quarter valued at about $36,000. Jane Street Group LLC grew its holdings in Century Therapeutics by 166.2% in the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after buying an additional 29,992 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in Century Therapeutics in the 4th quarter valued at approximately $52,000. Sei Investments Co. bought a new position in Century Therapeutics in the 4th quarter worth approximately $53,000. Finally, Barclays PLC lifted its holdings in shares of Century Therapeutics by 283.6% during the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after buying an additional 45,797 shares during the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.